Phase II randomized trial of docetaxel (D) monotherapy vs epirubicin plus docetaxel (ED) as neoadjuvant treatment of operable breast cancer (BC) No significant financial relationships to disclose.
Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer
Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer Between 2012 and 2015, blood samples were prospectively collected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback